Rapidemic

Rapidemic is an early-stage diagnostics company developing a proprietary molecular testing platform for the rapid and accurate detection of STIs like Chlamydia and Gonorrhea at the point of care. The company aims to address the critical gap in current diagnostics, which are often either slow but accurate (central lab PCR) or fast but unreliable (rapid antigen tests). Backed by notable grants and venture funding, including support from the Bill & Melinda Gates Foundation, Rapidemic is positioning itself to capture a significant share of the global STI testing market by enabling single-visit diagnosis and at-home testing.

Patented molecular detection platform using a proprietary nucleic acid amplification system integrated with a universal, easy-to-read detection method. Designed for rapid, accurate, decentralized identification of pathogens like Chlamydia trachomatis and Neisseria gonorrhoeae.

Rapidemic competes in the point-of-care molecular diagnostics space. Incumbents like Cepheid (owned by Danaher) offer accurate but relatively slower and more expensive cartridge-based systems for clinics. The competitive threat also comes from other startups developing rapid molecular platforms and from traditional, less accurate rapid antigen tests. Rapidemic's differentiation hinges on achieving a superior combination of speed, ease-of-use, and low cost while maintaining lab-grade accuracy.